The Founder of Coinbase Is Going to Research Immortality

marsbit2026-06-03 tarihinde yayınlandı2026-06-03 tarihinde güncellendi

Özet

Coinbase founder Brian Armstrong has co-founded NewLimit, a longevity biotech startup, which just raised $435 million in a Series C funding round led by Peter Thiel’s Founders Fund. The round values the company at $3.1 billion, more than triple its valuation from a year ago. NewLimit is developing drugs aimed at reversing cellular aging to extend human healthspan. Its approach builds on Nobel Prize-winning research on cellular reprogramming (Yamanaka factors), with a focus on identifying specific gene combinations that can restore younger cell function. The company plans to begin human clinical trials next year, initially targeting alcohol-related liver disease as a form of accelerated aging. Founded in 2021 by Armstrong alongside biotech investor Blake Byers and scientist Jacob Kimmel, NewLimit has now raised over $700 million across multiple rounds. It joins a growing field of well-funded longevity ventures backed by tech billionaires, including Sam Altman’s Retro Biosciences and Jeff Bezos-backed Altos Labs, reflecting a surge of interest in using science to combat aging and extend healthy lifespan.

Author | Azuma(@azuma_eth)

At 3:00 AM Beijing time on June 3, longevity technology startup NewLimit announced the completion of a $435 million Series C funding round. This round was led by Peter Thiel's fund Founders Fund, with continued participation from Abstract Ventures, Kleiner Perkins, NFDG, Eli Lilly Ventures, Valor Equity Partners, among others, while also introducing new investors such as Thrive Capital, Greenoaks, and Quiet Capital.

A WSJ report indicated that NewLimit's valuation in this round reached $3.1 billion, more than triple its valuation from a year ago.

In its funding announcement, NewLimit revealed that following breakthrough research achievements, the company is advancing longevity medicine into the human clinical trial stage. Its first drug targeting alcohol-related liver disease is expected to commence clinical trials next year.

NewLimit also emphasized: "By reprogramming cell age, humans may achieve longer health spans, and now, we are closer than ever to the goal of delaying or even reversing aging."

The Founder Turns Out to Be an Old Acquaintance

It is worth mentioning that one of NewLimit's co-founders is none other than our old acquaintance — Coinbase founder and CEO Brian Armstrong.

In 2021, Brian Armstrong, together with former GV partner and bioengineer Blake Byers and stem cell biologist Jacob Kimmel, invested $110 million to establish NewLimit in South San Francisco.

Picture: The NewLimit founding team

Prior to this funding round, NewLimit had already completed three rounds of financing, as detailed below.

May 2023: Completed a $40 million Series A round, with investors including Dimension, Founders Fund, and Kleiner Perkins;
May 2025: Completed a $130 million Series B round, reaching a valuation of $810 million, led by Kleiner Perkins, with participation from Founders Fund, Khosla Ventures, and Human Capital, among others;
October 2025: Received an additional $45 million investment, bringing the post-money valuation to $1.62 billion, with investors including Lilly Ventures, Duke University, Section 32, etc.;

According to NewLimit's official introduction, the company is dedicated to developing drugs that can extend human health span — "As humans age, cellular function gradually declines, making people more susceptible to diseases. It was once believed that aging was inevitable, but emerging science shows that the aging process can be reversed at the cellular level. We are developing the first drugs based on these discoveries to restore the youthful function of aging cells."

In simpler terms, NewLimit is using scientific methods to research immortality!

Reversing Aging is Not a Fantasy

Over the past few decades, while the scientific community has long recognized the link between aging and cellular functional decline, it could not precisely find a way to make cells "rejuvenate." The turning point came in 2006 when Japanese scientist Shinya Yamanaka discovered that activating just a few specific transcription factors could reprogram adult cells into a youthful state resembling embryonic stem cells. This discovery was later named "Yamanaka Factors" and helped him win the 2012 Nobel Prize in Physiology or Medicine.

Odaily Note: Picture shows Shinya Yamanaka speaking in Tokyo

Yamanaka's research first proved something previously considered impossible — that cellular age is not irreversible. And the story told by NewLimit is built precisely upon this discovery.

NewLimit writes on its website: "Our drugs can reprogram a cell's epigenome to a younger state by activating specific transcription factor genes. We already know this reversal is possible. However, for different cell types, exactly which combinations of transcription factors are needed to restore their youthful function remains unknown. Finding and discovering these effective payloads is the core challenge of our work."

NewLimit's strategy is to first target a specific disease to obtain drug approval, and then explore broader applications. As mentioned earlier, NewLimit is advancing a drug for alcohol-related liver disease into clinical trials.

NewLimit Co-founder and CEO Jacob Kimmel further explained, "Liver disease can actually be viewed as an 'accelerated version of aging,' it just presents the aging process that everyone experiences in a faster and more intense manner."

The Biggest Investors in This Sector Are All Billionaires

NewLimit is not the only tech company currently targeting "immortality."

In 2022, Sam Altman invested $180 million in Retro Biosciences, which is developing drugs to rejuvenate aging cells. Last month, Retro Biosciences disclosed its valuation had reached $1.8 billion.

Furthermore, Altos Labs, reportedly backed by Jeff Bezos's funding, also launched in 2022 with $3 billion and has since raised nearly twice that amount in total funding.

It's easy to see that from Peter Thiel to Sam Altman to Jeff Bezos, the biggest investors in this sector are without exception super-rich individuals at the pinnacle of technology and wealth. Peter Thiel has publicly expressed extreme aversion to death, advocating similar views on multiple occasions: "Death is humanity's greatest enemy, yet we treat it as a natural law..."

The logic behind these tech titans' willingness to invest hundreds of millions is not hard to understand — when wealth and power reach their peak, time becomes the only enemy, the only luxury that cannot be bought directly with money.

Having earned enough money, "how to live longer" becomes the greatest challenge.

İlgili Sorular

QWhat is NewLimit, and what is its primary goal?

ANewLimit is a longevity biotechnology startup. Its primary goal is to develop drugs to extend human healthspan by reversing the aging process at the cellular level.

QWho is the notable co-founder of NewLimit mentioned in the article?

AThe notable co-founder is Brian Armstrong, who is also the founder and CEO of the cryptocurrency exchange Coinbase.

QWhat scientific breakthrough is NewLimit's research based on?

ANewLimit's research is based on the discovery of the 'Yamanaka Factors' by Japanese scientist Shinya Yamanaka in 2006, which showed that adult cells can be reprogrammed into a younger, pluripotent state.

QHow much funding did NewLimit recently raise and at what valuation?

ANewLimit recently raised $435 million in a Series C funding round, which valued the company at $3.1 billion.

QWhy are super-wealthy tech figures like Peter Thiel and Sam Altman investing in longevity companies?

AFor super-wealthy individuals, time is seen as the ultimate luxury that money cannot directly buy. After achieving immense wealth and power, extending their healthspan and potentially reversing aging becomes a primary focus.

İlgili Okumalar

When Google Also 'Prints Stocks' to Build AI, Whose Narrative is Shattering the High Valuations of Neocloud?

Google has announced its first equity financing since 2005, a series of moves totaling $80 billion that signal a strategic challenge to Nvidia's GPU dominance in the AI compute market. This impacts "Neocloud" companies like CoreWeave, Nebius, and IREN, whose valuations are heavily tied to Nvidia's perceived uniqueness. Google's three-part strategy involves: launching new TPU chips (TPU 8t/8i) and selling them to third parties for the first time; forming a $25 billion compute-as-a-service joint venture with Blackstone; and raising ~$50 billion in new equity (part of an $80B package) to fund AI infrastructure, underscoring the massive capital demands even for tech giants. This marks a divergence from Microsoft's path. Microsoft, lacking a mature in-house AI chip, relies heavily on outsourcing to Neocloud providers using Nvidia GPUs. Google, with its proprietary TPU, is pursuing vertical integration—building its own data centers, selling chips, and competing directly with Neocloud services. While Neocloud firms have strong near-term revenue from locked-in Nvidia GPU contracts (e.g., CoreWeave's ~$100B backlog), Google's moves undermine their long-term valuation narrative based on Nvidia's sole supremacy and perpetual supply shortage. TPU performance claims and adoption by firms like Anthropic add credibility to Google's alternative. The AI compute market is transitioning from a uniform seller's market to a layered one: top AI labs are diversifying their hardware stacks; hyperscalers are pursuing different chip strategies; and financing costs will become a critical differentiator, favoring players like Google with lower capital costs. Key metrics to watch include the progress of the Google-Blackstone JV, expansion of the TPU customer base beyond Anthropic, and potential shifts in Microsoft's sourcing strategy. If Google succeeds on these fronts, the Neocloud investment thesis will require significant reassessment.

marsbit13 dk önce

When Google Also 'Prints Stocks' to Build AI, Whose Narrative is Shattering the High Valuations of Neocloud?

marsbit13 dk önce

Jensen Huang's Latest Forecast on Marvell Valuation: Interconnect Business Guidance Raised Over 70%, 2028 Revenue Estimated at $16.5 Billion

Marvell has significantly raised its AI-driven revenue guidance after a strong showing at the Evercore TMT conference, buoyed by robust orders. The company now forecasts fiscal 2027 revenue of approximately $11.5 billion, with its Interconnect business growth projection lifted from ~50% to over 70%. Current growth is fueled by mature "beyond the rack" products like PAM DSPs, TIAs, and pluggable optical modules. However, the more strategically important "in the rack" segment, including co-packaged optics (CPO), is still preparing for 2027 mass production, targeting several hundred million dollars in annualized revenue by 2028. While Marvell's custom ASIC business aims to double next year to over $4 billion, and it benefits from partnerships like the one with NVIDIA, its high valuation already incorporates substantial future optimism. The company faces competition from Broadcom, which holds a scale advantage. The key uncertainty remains the successful large-scale deployment of CPO technology, including yield, cost curves, and customer adoption. Execution milestones in 2027 will be critical to validate the current growth narrative and sustain the elevated stock price.

marsbit16 dk önce